Physician profile
William J Budd
NPI 1861486953
$4,149.90
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $235 · 2021: $1,037 · 2022: $819 · 2023: $1,614 · 2024: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.51 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $354.27 | 2020-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $338.25 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $291.68 | 2019-2023 | Repatha, Otezla, Evenity |
| Pfizer INC. | $248.11 | 2019-2024 | |
| Glaxosmithkline, LLC. | $244.80 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.20 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $194.08 | 2019-2023 | |
| Amarin Pharma, INC. | $179.80 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.19 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $142.29 | 2019 | |
| Exact Sciences Corporation | $113.41 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $111.53 | 2021-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $102.56 | 2021-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $94.50 | 2021-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Budd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.